"GLP-1 face" (sometimes called "Ozempic face") is an informal term for a gaunt or aged facial appearance that can follow rapid fat loss in the face, combined with reduced skin elasticity. Fast, substantial weight loss by any route can do this, and GLP-1s produce that kind of loss. Whether the drugs add anything beyond the weight loss itself is still unsettled: in a 2026 survey study, people using GLP-1s reported more facial volume loss than people losing a similar amount of weight by other means, but the authors noted their design couldn't separate a drug effect from the weight loss. It isn't a recognized medical diagnosis. For what may help and when it's worth mentioning to your prescriber, see our full guide on GLP-1 face: prevention, skincare, and what it actually signals. Survey source: Rao et al., Dermatology and Therapy, 2026 (external link).
GLP-1 face
A colloquial term for facial volume loss and skin laxity that can accompany rapid, significant weight loss on GLP-1 medications.
Updated Sep 26, 2026
Was this helpful?
Revision history
Last updated · 4 revisions recorded.
Show what changed
- v4
Body revised
- v3
Body revised
- v2
Body revised
- v1
Existing article recorded at the start of version history
Improve this page
Community notes
Share helpful experiences and questions. Notes are reviewed before publication and do not replace medical advice.
Loading notes…
New submissions are currently paused. Existing approved notes remain available.
Related terms
- Hazard ratio — A statistic from clinical trials that compares how often an event happens over time in one group versus another; below 1 means a lower rate in the treated group.
- Sharps container — A puncture-resistant container for safely collecting used needles, pen needles, and syringes until they can be disposed of according to local rules.
- Oral semaglutide — Semaglutide taken as a once-daily pill instead of a weekly injection: Rybelsus and its reformulation, Ozempic tablets, for type 2 diabetes, and the Wegovy pill for weight management.
Related guides
- Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis — GLP-1 medications slow the stomach, but the trials show the effect is smaller and fades more than most people assume, especially with the long-acting weekly drugs. This guide covers how much slower, whether it lasts, how gastric emptying is measured, how it differs from gastroparesis, and why the "food ferments in your stomach" claim has no evidence behind it.
- Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration — Missed a few weeks of Wegovy, Zepbound, Ozempic, Trulicity, Saxenda, or a GLP-1 pill? Only four labels spell out when to restart at a lower dose: Wegovy injection after 2 missed weekly doses, Saxenda and Victoza after more than 3 days, and Foundayo after 7 missed daily doses. The rest are silent on long gaps. This by-drug reference separates what each label says from what's left to your prescriber, and explains why going straight back to your old dose is risky.
- Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo — There are now three GLP-1 pills in the US, and they aren't interchangeable: oral semaglutide for diabetes (Rybelsus, now sold as Ozempic tablets), oral semaglutide for weight (the Wegovy pill), and orforglipron (Foundayo). Here's how they compare on approval, how you take them, what the trials found, side effects, cost, and what you give up versus a weekly injection.